Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for J. Joseph Baxter
14.36
+0.08 (0.53%)
Real-time:   11:07AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.13 - 14.58
52 week 8.87 - 15.34
Open 14.20
Vol / Avg. 260,059.00/1.18M
Mkt cap 1.83B
P/E     -
Div/yield     -
EPS -1.18
Shares 127.30M
Beta 1.40
Inst. own 90%
Nov 5, 2014
Q3 2014 Nektar Therapeutics Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jul 31, 2014
Q2 2014 Nektar Therapeutics Earnings Call - Webcast
Jul 31, 2014
Q2 2014 NEKTAR THERAPEUTICS Earnings Release
Jul 8, 2014
Nektar Therapeutics at Piper Jaffray Catalyst Symposium (1:1 Conference)
Jun 25, 2014
NEKTAR THERAPEUTICS Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -114.46% -108.79%
Operating margin -80.37% -80.67%
EBITD margin - -71.08%
Return on average assets -27.13% -34.75%
Return on average equity - -
Employees 445 -
CDP Score - -

Address

455 Mission Bay Boulevard South
SAN FRANCISCO, CA 94158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is consisted of early to late stage drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve both small molecule and biologic drug candidates. It creates drug candidates by using its advanced polymer conjugate technologies to modify the chemical structure of pharmacophores to create new molecular entities. Its drug candidate, naloxegol (formerly known as NKTR-118), is an oral opioid antagonist, which has completed Phase III clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain. Its second drug candidate, etirinotecan pegol (also known as NKTR-102), is a topoisomerase I inhibitor, which is under Phase III clinical study as of December 31, 2012.

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
John Nicholson Chief Financial Officer, Senior Vice President
Age: 62
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 48
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Gil M. Labrucherie J.D. Senior Vice President, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 60
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 55
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 62
Bio & Compensation  - Reuters